Table 1.

Summarized study results

Authors	Examined patients	Antibody prevalence	Thrombotic complications
Devreese et al.	31	16/31 LAC; 23/31 any aPL	9, thereof 7 positive for any aPL
Harzallah et al.	56	25/56 LAC; 5/56 IgG/IgM aCL or IgG/IgM anti-β2GPI	–
Gatto et al.	122	22.2% LAC; 13.4% IgG aCL; 2.7% IgM aCL, 6.3% IgG anti-β2GPI; 7.1% IgM anti-β2GPI	18/46
Galeano-Valle et al.	24	2/24 IgM aCL and IgM anti-β2GPI	24
Le Joncour et al.	104	35/104 aCL; 9/104 anti-β2GPI; 21/104 LAC; 49/104 any aPL	11; 64% positive for any aPL
Karahan et al.	31	8/31 any aPL; 6/26 LAC; 2/31 IgM aCL; 0/31 IgG/IgM anti-β2GPI; 2/31 IgA anti-β2GPI	–
Bowles et al.	34	31/34 LAC	–
Helms et al.	57	50/57 LAC	–
Borghi et al.	122	5.7/6.6% IgG/IgM aCL; 15.6/6.6/9.0%, IgG/IgA/IgM anti-β2GPI	16
Trahtemberg et al.	22	13/22 IgG aCL; 7/22 IgM aCL	–
Zuo et al.	172	52% any aPL	–
Amezcua-Guerra et al.	21	12/21 any aPL; 10%/14% IgG/IgM aCL	2
Hamadé et al.	41	7/41 any aPL; 5/41 LAC	9, thereof 2 positive for any aPL
Cristiano et al.	92	2/44 (early infection); 3/48 (late infection)	–
Reyes Gil et al.	68	30/68 LAC; 1/68 IgM aCL and IgM anti-β2GPI	19/30 (positive LAC)
Pineton de Chambrun et al.	25	92% LAC; 52% IgG/IgM aCL; 12% IgG/IgM anti-β2GPI	6, thereof all positive for any aPL
Xiao et al.	66 (critical condition); 13 (non-critical condition)	31/66 any aPL(IgG/IgM/IgA aCL and anti-β2GPI); 0/13 any aPL	–
Previtali et al.	35 (PM)	5/35 any aPL(IgG/IgA/IgM aCL and anti-β2GPI)	35